I'm LongbridgeAI, I can summarize articles.The Week
CSOP NIKKEI225 closed the week at HK$133.45, down 4.78% from the previous close of HK$140.15. The Hang Seng Index lost 0.35%, leaving this ETF about 4.43 percentage points behind. Trading was soft across four sessions: it opened near HK$140.00 on Monday, slipped through the week, touched a low of HK$131.05 on Wednesday, and ended Thursday at HK$133.45. That puts the price below its 20-day moving average of HK$137.11, after having traded closer to the 60-day range high of HK$143.65 earlier in October.
Sector News
The Nikkei 225 fell sharply this week. On 13 October it dropped as much as 2.5% intraday before closing 1.8% lower. The selling intensified on 15 October, when the index sank 4.8% by midday and closed down 5.4% at 64,095.94. The yen hovered around 158. Markets then staged a rebound on 16 October, with the Nikkei 225 up 1.4% and snapping a six-day losing streak, though the weekly loss still came to 5.37%. Hong Kong-listed tech and biotech ETFs showed isolated moves with little read-across to this Japan-focused fund.
The Week Ahead
Hong Kong macro data lands on 22 October: the unemployment rate (prior 3.8) and the composite CPI (prior 1.7). Both speak to local labour conditions and inflation pressure, which can colour risk appetite in Hong Kong equities. In Japan, the Nikkei 225 has just broken a losing streak, so the question is whether the 16 October rebound can hold; further volatility there would feed directly into this ETF.
In Short
The fund lagged the Hang Seng Index by more than 4 percentage points, driven by rapid sell-offs and a partial rebound in Japanese equities that pushed the price below its 20-day moving average. The latest session’s flows show medium-lot money net buying roughly HK$1.2m and small-lot money net buying about HK$0.07m, a mildly positive tilt that sits awkwardly against the week’s drawdown. What to watch is whether the Nikkei 225 can sustain its recovery from the sharp drop, alongside Hong Kong macro readings for overall sentiment.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
